These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38180028)

  • 1. Non-clinical evaluation of local and systemic immunity induced by different vaccination strategies of the candidate tuberculosis vaccine M72/AS01.
    Ouaked N; Demoitié MA; Godfroid F; Mortier MC; Vanloubbeeck Y; Temmerman ST
    Tuberculosis (Edinb); 2023 Dec; 143():102425. PubMed ID: 38180028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults.
    Day CL; Tameris M; Mansoor N; van Rooyen M; de Kock M; Geldenhuys H; Erasmus M; Makhethe L; Hughes EJ; Gelderbloem S; Bollaerts A; Bourguignon P; Cohen J; Demoitié MA; Mettens P; Moris P; Sadoff JC; Hawkridge A; Hussey GD; Mahomed H; Ofori-Anyinam O; Hanekom WA
    Am J Respir Crit Care Med; 2013 Aug; 188(4):492-502. PubMed ID: 23306546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults.
    Montoya J; Solon JA; Cunanan SR; Acosta L; Bollaerts A; Moris P; Janssens M; Jongert E; Demoitié MA; Mettens P; Gatchalian S; Vinals C; Cohen J; Ofori-Anyinam O
    J Clin Immunol; 2013 Nov; 33(8):1360-75. PubMed ID: 24142232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.
    Idoko OT; Owolabi OA; Owiafe PK; Moris P; Odutola A; Bollaerts A; Ogundare E; Jongert E; Demoitié MA; Ofori-Anyinam O; Ota MO
    Tuberculosis (Edinb); 2014 Dec; 94(6):564-78. PubMed ID: 25305000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.
    Penn-Nicholson A; Geldenhuys H; Burny W; van der Most R; Day CL; Jongert E; Moris P; Hatherill M; Ofori-Anyinam O; Hanekom W; ; Bollaerts A; Demoitie MA; Kany Luabeya AK; De Ruymaeker E; Tameris M; Lapierre D; Scriba TJ
    Vaccine; 2015 Jul; 33(32):4025-34. PubMed ID: 26072017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
    Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
    AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.
    van den Berg RA; De Mot L; Leroux-Roels G; Bechtold V; Clement F; Coccia M; Jongert E; Evans TG; Gillard P; van der Most RG
    Front Immunol; 2018; 9():564. PubMed ID: 29632533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study.
    Gillard P; Yang PC; Danilovits M; Su WJ; Cheng SL; Pehme L; Bollaerts A; Jongert E; Moris P; Ofori-Anyinam O; Demoitié MA; Castro M
    Tuberculosis (Edinb); 2016 Sep; 100():118-127. PubMed ID: 27553419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.
    Kumarasamy N; Poongulali S; Bollaerts A; Moris P; Beulah FE; Ayuk LN; Demoitié MA; Jongert E; Ofori-Anyinam O
    Medicine (Baltimore); 2016 Jan; 95(3):e2459. PubMed ID: 26817879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Analysis of a Trial of M72/AS01
    Tait DR; Hatherill M; Van Der Meeren O; Ginsberg AM; Van Brakel E; Salaun B; Scriba TJ; Akite EJ; Ayles HM; Bollaerts A; Demoitié MA; Diacon A; Evans TG; Gillard P; Hellström E; Innes JC; Lempicki M; Malahleha M; Martinson N; Mesia Vela D; Muyoyeta M; Nduba V; Pascal TG; Tameris M; Thienemann F; Wilkinson RJ; Roman F
    N Engl J Med; 2019 Dec; 381(25):2429-2439. PubMed ID: 31661198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.
    Rodo MJ; Rozot V; Nemes E; Dintwe O; Hatherill M; Little F; Scriba TJ
    PLoS Pathog; 2019 Mar; 15(3):e1007643. PubMed ID: 30830940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial.
    Kumarasamy N; Poongulali S; Beulah FE; Akite EJ; Ayuk LN; Bollaerts A; Demoitié MA; Jongert E; Ofori-Anyinam O; Van Der Meeren O
    Medicine (Baltimore); 2018 Nov; 97(45):e13120. PubMed ID: 30407329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01
    Ullah I; Bibi S; Ul Haq I; Safia ; Ullah K; Ge L; Shi X; Bin M; Niu H; Tian J; Zhu B
    Front Immunol; 2020; 11():1806. PubMed ID: 33133057
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity and Safety of the M72/AS01
    Ji Z; Jian M; Chen T; Luo L; Li L; Dai X; Bai R; Ding Z; Bi Y; Wen S; Zhou G; Abi ME; Liu A; Bao F
    Front Immunol; 2019; 10():2089. PubMed ID: 31552037
    [No Abstract]   [Full Text] [Related]  

  • 16. Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens.
    Mortier MC; Jongert E; Mettens P; Ruelle JL
    BMC Immunol; 2015 Oct; 16():63. PubMed ID: 26493839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01
    Clark RA; Weerasuriya CK; Portnoy A; Mukandavire C; Quaife M; Bakker R; Scarponi D; Harris RC; Rade K; Mattoo SK; Tumu D; Menzies NA; White RG
    BMC Med; 2023 Aug; 21(1):288. PubMed ID: 37542319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
    Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
    PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2b Controlled Trial of M72/AS01
    Van Der Meeren O; Hatherill M; Nduba V; Wilkinson RJ; Muyoyeta M; Van Brakel E; Ayles HM; Henostroza G; Thienemann F; Scriba TJ; Diacon A; Blatner GL; Demoitié MA; Tameris M; Malahleha M; Innes JC; Hellström E; Martinson N; Singh T; Akite EJ; Khatoon Azam A; Bollaerts A; Ginsberg AM; Evans TG; Gillard P; Tait DR
    N Engl J Med; 2018 Oct; 379(17):1621-1634. PubMed ID: 30280651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses.
    Coccia M; Burny W; Demoitié MA; Gillard P; van den Berg RA; van der Most R
    PLoS One; 2022; 17(11):e0276505. PubMed ID: 36355775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.